Vast clinical trial undertaken on psychiatric patients in Switzerland
Between 1946 and 1980, at least 3,000 people served as "guinea pigs" at the Münsterlingen Psychiatric Clinic in northeast Switzerland, according to a report published on Monday. The authorities in the canton of Thurgau apologised to the victims of these drug tests.
This content was published on
3 minutes
The 300-page study highlights the key role played by doctor and clinic director Roland Kuhn (1912-2005). Kuhn was involved in the development of the first tricyclic antidepressant, Tofranil. At least 67 different substances on groups of different sizes, sometimes reaching up to 1,000 people, were tested. Some 25,000 tablets of an antidepressant never before marketed have been found in metal cans.
From the mid-1960s onwards, Kuhn’s methods no longer met scientific standards but the authorities and the pharmaceutical industry allowed and even financed his research, according to Jakob Stark, the president of the Thurgau State Council. Patients rarely volunteered for these experiments and they were also rarely informed about the drugs they received.
Controls, the study found, were insufficient. There have been medical complications and even deaths associated with the clinical trials, although there is some uncertainty regarding the exact causes of death.
In addition to the clinic and the pharmaceutical companies, a vast network of institutions and people were involved in the trials: patients’ caretakers, private doctors, other clinics, authorities. The pharmaceutical industry paid Kuhn millions of francs to carry out these tests.
The Thurgau authorities found the extent of the experiments undertaken particularly disturbing. They are troubled by the fact that concoctions were administered to patients who did not belong to the test groups. Another source of concern is the administration of the trial on highly vulnerable individuals such as children, adolescents or people with serious or chronic diseases.
Novartis Archives
The report was carried out at the request of the canton by an independent and interdisciplinary research team under the direction of Marietta Meier, a professor at the University of Zurich. It took three and a half years to complete and cost about CHF1 million ($1 million). The authors relied on the archives of the Münsterlingen Clinic (TG), the estate of Roland and Verena Kuhn-Gebhart, as well as the archives of Swiss pharmaceutical giant Novartis.
Drugs have been tested on patients in psychiatric institutions in several Swiss cantons in the past, particularly in Basel and Lucerne. Historical work is underway. In the canton of Vaud, last year the parliament voted against commissioning a report on possible tests of unauthorised medicines between 1940 and 1980.
More
More
Fresh claims of drugs tested on psychiatric patients
This content was published on
Katharina Brandenberger shared information obtained from archived medical records for her doctorate, with the Swiss Public Television, SRF, programme, Schweiz Aktuell. She claims that the research department of the University Psychiatric Clinic Burghölzli in Zurich carried out the testing on patients. In the 1970s alone, 44 different drugs were tested. If the patients refused to…
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
This content was published on
The Locarno Film Festival is considering moving from the beginning of August to the second half of July for its 80th edition in 2027.
Council of Europe head Alain Berset visits Georgia
This content was published on
The Secretary General of the Council of Europe, Alain Berset, is visiting Georgia, which has been rocked by a political crisis, from Wednesday.
Swiss politician who shot at Jesus faces criminal proceedings
This content was published on
The Zurich public prosecutor's office has opened criminal proceedings against politician Sanija Ameti. It is investigating whether she disrupted freedom of religion and worship.
Switzerland must be able to control immigration, says head of business federation
This content was published on
Switzerland must be able to control immigration itself if it "exceeds the tolerable limits", says Christoph Mäder, president of Economiesuisse, the Swiss Business Federation.
This content was published on
The film Reinas by Klaudia Reynicke, a Swiss-Peruvian-Spanish co-production, has missed out on an Oscar nomination for Best Foreign Film.
Raiffeisen Switzerland CEO steps down unexpectedly
This content was published on
Raiffeisen Switzerland CEO Heinz Huber is stepping down at the end of the year. This means that Switzerland's second-largest banking group after UBS is looking for a new CEO.
Artificial intelligence has yet to affect election results
This content was published on
Artificial intelligence has not yet had a decisive influence on election results, according to Swiss researchers who analysed this year's elections in almost 100 countries.
Swiss ski rescuers attended 14,000 accidents last winter
This content was published on
Last season, piste rescue services treated 14,000 people in Swiss ski resorts. Some 80% of accidents occurred while skiing.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Tests on humans in psychiatric clinic uncovered
This content was published on
Documents seen by the programme Schweiz AktuellExternal link – broadcast on Friday evening – show that in 1957 the not-yet approved drug G22355 was given to at least 18 male and female patients in the then Cure and Care Institution in Herisau in canton Appenzell Outer Rhodes. The drug was for depression and was delivered…
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
WHO adopts watered-down resolution on drug transparency
This content was published on
The World Health Organization (WHO) has adopted a resolution to improve transparency on drug prices but some people say it doesn't go far enough.
Pharma turns to big data to gauge care and pricing
This content was published on
Struggling to keep pace with digitisation, big pharma companies are turning to big data to drive future growth. Swiss-based Novartis is no different.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.